Review Article

COVID-19 Related Coagulopathy

10.37696/nkmj.772162

  • Seval AKPINAR

Received Date: 21.07.2020 Accepted Date: 10.09.2020 Nam Kem Med J 2020;8(3):564-569

novel coronavirus of zoonotic origin named “severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)” emerged at the end of 2019, in Wuhan province of China. The infection called COVID-19 was declared by World Health Organization a global pandemic. Coronavirüs disease-2019 (COVID-19) is frequently associated with a hypercoagulable state as a result of endothelial injury, stasis and increased levels of circulating protrombotic factors. Especially patients in intensive care units have an increased risk for venous thromboembolism despite prophylactic anticoagulant treatment. In this review, we summarized current data regarding pathophysiology, coagulation parameters, evaluation and management of COVID-19 associated coagulopathy.

Keywords: COVID-19, thromboembolism, thrombosis, intravascular coagulation